Jefferies Cuts Price Target on Surgery Partners, Inc. (SGRY) to $24 Following 3Q
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies maintained a Buy rating on Surgery Partners, Inc. (NASDAQ: SGRY), and cut the price target to $24.00 (from $27.00), following the company's 3Q earnings report. SGRY put up strong SS rev growth of +10.3% in Q3, which highlights the company's ability to continue driving consistent, double-digit same-store growth. Guidance was adjusted down due to the timing of acquisitions & weather related issues. SGRY adjusted its 2016 EBITDA guidance to $179-$184MM (prior $184-$191MM) as a result of its 4 Q3 acquisitions closing at the end of the quarter rather than early in the quarter as planned.
Analyst Brian Tanquilut commented, "We remain bullish on SGRY given our view that 1) the company is wellpositioned to continue delivering very healthy organic growth (+10.3% in Q3 despite expected July softness), 2) tailwinds from new complex procedures (i.e., ortho) shifting to ASCs will provide an incremental LT growth driver, & 3) a strong M&A pipeline will continue to boost growth. Trading at 0.7x PE/G & 9.5x EBITDA, we believe SGRY is compelling at current levels."
Shares of Surgery Partners closed at $14.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades Essex Property Trust (ESS) to Overweight
- Morgan Stanley Downgrades Workiva (WK) to Equalweight, Says Owning The Stock Could be Challenging In 2017
- Wal-Mart (WMT) PT Lowered to $70 at Morgan Stanley, Says Food Price Deflation Is A Wildcard, Concerned Over Slowdown In Site Visitations
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!